ArticleBMC medicine2026
Relative leukocyte telomere length and the risk of lung cancer progression in individuals with pulmonary nodules.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe role of leukocyte telomere length (LTL) in predicting lung cancer risk remains controversial, particularly in individuals with pulmonary nodules.
methodsWe conducted a prospective cohort study of 1803 individuals with pulmonary nodules identified by chest CT, with no prior history of cancer. Relative LTL (rLTL) was measured using quantitative PCR. Lung cancer incidence and mortality were ascertained through linkage with the Chongqing Chronic Disease Surveillance System using ICD-10 code. Associations between rLTL and lung cancer risk were assessed using Cox proportional hazards models, with adjustment for demographic, clinical, and radiological variables. We further evaluated the incremental predictive value of rLTL when added to five established lung nodule malignancy risk models using AUC, NRI, and IDI.
resultsPatients with longer rLTL had an increased risk of lung cancer (adjusted HR = 7.26 (1.71-30.87); P = 0.007), compared with those with shorter rLTL. Subgroup analyses suggested stronger associations in younger individuals and women, although interactions were non-significant. rLTL remained an independent predictor across all five lung nodule models (HR range, 1.47-1.72). While the improvements in AUC and IDI were modest, NRI was significantly improved in all models (range, 0.380-0.847, all P < 0.05), suggesting better risk reclassification.
conclusionIn this health check-up cohort of individuals with pulmonary nodules, longer rLTL was independently associated with increased lung cancer risk. Our findings highlight a potentially paradoxical role of telomere biology in lung carcinogenesis and suggest that rLTL may serve as a useful biomarker for malignancy risk stratification in nodule surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.